ZIM
ODT

Zacks Investment Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Zacks Investment Management’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-16,886
Closed -$227K – 596
2020
Q3 		$227K Sell
16,886
-1,753
-9% -$49.7K ﹤0.01% 477
2020
Q2 		$789K Buy
+18,639
New +$603K 0.02% 338

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Zacks Investment Management's ODT Position: Q4 2020 in Review

Zacks Investment Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2020, closing a stake of 16,886 shares — an estimated $227K sold.

Zacks Investment Management first reported a position in ODT in Q2 2020 and held it in 2 quarters. The position peaked at $789K in Q2 2020. 94 funds tracked by Wall St. Rank hold ODT as of Q4 2020.

  • Zacks Investment Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Zacks Investment Management sold 16,886 Odonate Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $227K.
  • Zacks Investment Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Zacks Investment Management's Odonate Therapeutics, Inc. Common Stock position peaked at $789K in Q2 2020.
  • 94 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Zacks Investment Management's 13F filing for Q4 2020, filed 16 Feb 2021.